DGAP-News

NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT

DGAP-News: Neovacs S.A. / Key word(s): Financing
NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT

23.10.2014 / 08:30

---------------------------------------------------------------------

NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT

Paris, 23 October 2014 - NEOVACS (Alternext Paris: ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, today
announced the signing of a financing project with Kepler Cheuvreux.

Neovacs has an innovative portfolio of vaccines in clinical and
pre-clinical stage, which will need several years to develop until
registration.

Some of these products should be subject of a licensing or co-development
agreement, assuring, thus a long lasting scientific partnership as well as
the co-financing of common projects.

In addition and in order to accompany its plan of development, Neovacs has
already been able to agree with Kepler Cheuvreux on a financing tool,
covering several years, including optional items, in order to be able to
raise funds according to the evolution of the company's financial needs.

Agreed in its principles by the management team of both companies, the
implementation of this project will be subject of detailed information at a
later stage.


About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy
technology platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary technology
for inducing a polyclonal immune response (covered by six patent families
that run until at least 2023) Neovacs is focusing its development efforts
on two active immunotherapies: TNF-Kinoid is being developed for the
treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis
and Crohn's disease, whereas IFNα-Kinoid is being developed for the
indication of lupus. Neovacs is also conducting preclinical works on
IFNα-Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related
Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the
treatment of allergies. The goal of the Kinoid approach is to enable
patients to have access to safe treatments with efficacy that is sustained
in these life-long diseases.


For more information on Neovacs, visit www.neovacs.fr


Press & Financial Communication France - Publicis

Stéphanie Tabouis
Aubane de Gélis
[phone]
[phone]
sté[e-mail]
[e-mail]



---------------------------------------------------------------------

23.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: [phone]
Fax: [phone]
E-mail: www.neovacs.fr
Internet: [e-mail]
ISIN: FR0004032746
WKN: A1CVKR
Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market


End of News DGAP News-Service
---------------------------------------------------------------------
292886 23.10.2014